Redeye returns with an updated assessment and a raised fair value range for Xbrane following the announced licensing deal with Biogen.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Xbrane Biopharma - Xciting and Increasingly Compelling Case

© Modular Finance, source Nordic Press Releases